Waterjet ablation therapy vs. urethral-sparing robot-assisted simple prostatectomy for large prostate volumes (>80 mL): results of a retrospective multicentric series according to the standardized BPH6 achievement.
Umberto Anceschi, Francesco Tedesco, Daniele Amparore, Eugenio Bologna, Giampaolo Siena, Loris Cacciatore, Salvatore Basile, Andrea Cocci, Francesco Prata, Rocco S Flammia, Sabrina De Cillis, Francesco Sessa, Alfredo M Bove, Lorenzo Viola, Andrea Iannuzzi, Alberto Ragusa, Aldo Brassetti, Riccardo Mastroianni, Gabriella Mirabile, Flavia Proietti, Leslie C Licari, Ashanti Zampa, Alberto Quarà, Michele Ortenzi, Enrico Checcucci, Cristian Fiori, Francesco Porpiglia, Andrea Minervini, Vito Pansadoro, Costantino Leonardo, Giuseppe Simone
{"title":"Waterjet ablation therapy vs. urethral-sparing robot-assisted simple prostatectomy for large prostate volumes (>80 mL): results of a retrospective multicentric series according to the standardized BPH6 achievement.","authors":"Umberto Anceschi, Francesco Tedesco, Daniele Amparore, Eugenio Bologna, Giampaolo Siena, Loris Cacciatore, Salvatore Basile, Andrea Cocci, Francesco Prata, Rocco S Flammia, Sabrina De Cillis, Francesco Sessa, Alfredo M Bove, Lorenzo Viola, Andrea Iannuzzi, Alberto Ragusa, Aldo Brassetti, Riccardo Mastroianni, Gabriella Mirabile, Flavia Proietti, Leslie C Licari, Ashanti Zampa, Alberto Quarà, Michele Ortenzi, Enrico Checcucci, Cristian Fiori, Francesco Porpiglia, Andrea Minervini, Vito Pansadoro, Costantino Leonardo, Giuseppe Simone","doi":"10.23736/S2724-6051.25.06084-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The introduction of minimally invasive techniques for BPH treatment aimed to balance de-obstruction with maintenance of ejaculatory function. The aim of this multicentric series was to compare outcomes of waterjet ablation therapy (WAT) versus urethral-sparing robot assisted simple prostatectomy (us-RASP) for large prostate volumes (PV>80 mL) according to BPH-6 metric.</p><p><strong>Methods: </strong>Four institutional BPH datasets were matched and queried for \"PV>80 mL\" (N.=86), \"WAT\" (Group A; N.=42) and \"us-RASP\" (Group B; N.=44). Baseline, perioperative and functional data according to BPH6 composite endpoint were compared between groups. Differences between continuous variables were assessed with t-test or Mann-Whitney U-test depending on their normal or not normal distribution, while Chi-square Test was used for categorical data. A two-sided P<0.05 was considered significant.</p><p><strong>Results: </strong>Patients treated with WAT showed lower preoperative PSA median values (3.5 vs. 7.07 ng/mL) (P<0.05). Regarding perioperative outcomes, patients treated with us-RASP revealed increased median operative time (110 vs. 70 mins), prolonged bladder irrigation time (24 vs. 37.2 hours), longer median hospital stay (5 vs. 4 days), respectively (all P<0.05). At a median follow-up of 43.7 months (IQR 33.8-49.7), the BPH6 achievement rate was comparable between groups (54.7% vs. 56.8%; P=0.964). In the WAT series 1-year ejaculatory dysfunction rate was 19.1% while in the us-RASP cohort was 13.6%, respectively (P=0.21). Retrospective design and the lack of a propensity-score matching represent main limitations of this study.</p><p><strong>Conclusions: </strong>Compared to us-RASP, WAT showed comparable symptom relief and ejaculatory function preservation for prostate gland >80 mL with benefit in terms of main perioperative outcomes at mid-term follow-up.</p>","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":"77 2","pages":"247-255"},"PeriodicalIF":4.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-6051.25.06084-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The introduction of minimally invasive techniques for BPH treatment aimed to balance de-obstruction with maintenance of ejaculatory function. The aim of this multicentric series was to compare outcomes of waterjet ablation therapy (WAT) versus urethral-sparing robot assisted simple prostatectomy (us-RASP) for large prostate volumes (PV>80 mL) according to BPH-6 metric.
Methods: Four institutional BPH datasets were matched and queried for "PV>80 mL" (N.=86), "WAT" (Group A; N.=42) and "us-RASP" (Group B; N.=44). Baseline, perioperative and functional data according to BPH6 composite endpoint were compared between groups. Differences between continuous variables were assessed with t-test or Mann-Whitney U-test depending on their normal or not normal distribution, while Chi-square Test was used for categorical data. A two-sided P<0.05 was considered significant.
Results: Patients treated with WAT showed lower preoperative PSA median values (3.5 vs. 7.07 ng/mL) (P<0.05). Regarding perioperative outcomes, patients treated with us-RASP revealed increased median operative time (110 vs. 70 mins), prolonged bladder irrigation time (24 vs. 37.2 hours), longer median hospital stay (5 vs. 4 days), respectively (all P<0.05). At a median follow-up of 43.7 months (IQR 33.8-49.7), the BPH6 achievement rate was comparable between groups (54.7% vs. 56.8%; P=0.964). In the WAT series 1-year ejaculatory dysfunction rate was 19.1% while in the us-RASP cohort was 13.6%, respectively (P=0.21). Retrospective design and the lack of a propensity-score matching represent main limitations of this study.
Conclusions: Compared to us-RASP, WAT showed comparable symptom relief and ejaculatory function preservation for prostate gland >80 mL with benefit in terms of main perioperative outcomes at mid-term follow-up.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
